share_log

Atara Biotherapeutics Receives FDA Clearance Of IND Application In Lupus Nephritis For ATA3219

Moomoo 24/7 ·  Feb 29 09:12

Second IND Clearance for ATA3219 Following Non-Hodgkin's Lymphoma (NHL) and First in an Autoimmune Disease Indication

Initial Clinical Data in NHL Anticipated in H2 2024 and for Lupus Nephritis in H1 2025

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment